STELA Dairy Research Centre, Nutraceuticals and Functional Foods Institute, Université Laval, Quebec, QC, Canada.
Cell Mol Life Sci. 2013 Aug;70(16):2947-67. doi: 10.1007/s00018-012-1202-3. Epub 2012 Oct 30.
Bacteriocin production is a widespread phenomenon among bacteria. Bacteriocins hold great promise for the treatment of diseases caused by pathogenic bacteria and could be used in the future as alternatives to existing antibiotics. The anti-infective potential of bacteriocins for inhibiting pathogens has been shown in various food matrices including cheese, meat, and vegetables. However, their inhibition of pathogens in vivo remains unclear and needs more investigation, due mainly to difficulties associated with demonstrating their health benefits. Many bacteriocins produced by established or potential probiotic organisms have been evaluated as potential therapeutic agents and interesting findings have been documented in vitro as well as in a few in vivo studies. Some recent in vivo studies point to the efficacy of bacteriocin-based treatments of human and animal infections. While further investigation remains necessary before the possibilities for bacteriocins in clinical practice can be described more fully, this review provides an overview of their potential applications to human and veterinary health.
细菌素的产生在细菌中是一种普遍现象。细菌素有很大的希望用于治疗由病原菌引起的疾病,并且将来可能会替代现有的抗生素。细菌素在包括奶酪、肉类和蔬菜在内的各种食品基质中抑制病原体的抗感染潜力已经得到了证明。然而,它们在体内抑制病原体的作用尚不清楚,需要进一步研究,主要是因为在证明其健康益处方面存在困难。许多由已建立或潜在的益生菌产生的细菌素已被评估为潜在的治疗剂,并且已经在体外和少数体内研究中记录了有趣的发现。一些最近的体内研究表明,基于细菌素的治疗方法对人类和动物感染的有效性。虽然在更全面地描述细菌素在临床实践中的可能性之前还需要进一步的研究,但本综述提供了它们在人类和兽医健康方面的潜在应用概述。